EUCTR2008-002140-41-DE进行中（未招募）不适用
Double-blind, placebo controlled, randomized study of vardenafil to determine efficacy on Erectile Dysfunction (ED) in men with ED and Metabolic Syndrome (ED-METABOLIC) - ED-METABOLIC
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1) Males aged 18 up to 64 (inclusive) years.
- •Note: It is possible that a label change occurs during the course of this study which would affect recommendations for initial dosing of vardenafil in patients aged 65 years and older for whom the current labeling recommends a starting dose of 5 mg. If this label change is granted by the European regulatory body (EMEA), investigators will subsequently be notified that patients >64 years of age may be enrolled as well. Details will be in accordance with that possible new labeling.
- •2) Stable, heterosexual relationship for at least 6 months.
- •3) A history of erectile dysfunction (ED) for at least 6 months, defined as the inability to achieve and maintain an erection of the penis sufficient to complete satisfactory sexual intercourse” by the NIH Consensus Development Panel on Impotence.
- •4) IIEF Erectile Function Domain entry score (at Visit 2): < 21 score points.
- •5) Documented metabolic syndrome according to the definition of the International Diabetes Foundation (IDF)7 (Appendix 10.2): Waist circumference (to be measured at the umbilicus), > 94 cm in European, Sub-Saharan Africans, Eastern Mediterranean and Middle East (Arab) populations, > 90 cm in ethnic South Asian, Chinese, ethnic South and Central Americans, > 85 cm in Japanese, or South and Central American men. In addition, at least two of the following criteria must be met: raised TG level > 150 mg/dl, or specifc treatment for this abnormality, reduced HDL cholesterol < 40 mg/dl, or specifc treatment for this abnormality, raised blood pressure systolic BP > 130 mm Hg and/or diastolic BP > 85 mm Hg, or treatment of previously diagnosed hypertension, raised fasting plasma glucose blood glucose (FPG) > 100 mg/dl or previously diagnosed type 2 diabetes.
- •6) Subjects motivated to obtain treatment for erectile dysfunction.
- •7) Documented, dated, written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A) Previous or current medical conditions
- •1) Any underlying cardiovascular condition, including unstable angina pectoris that would preclude sexual activity according to the NIH consensus report.1
- •2) History of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to visit 1 (= screening).
- •3) Uncontrolled atrial fibrillation / flutter at screening (defined as ventricular response rate = 100 bpm).
- •4) Resting hypotension (a resting systolic blood pressure of < 90 mm Hg) or hypertension (a resting systolic blood pressure > 170 mm Hg or a resting diastolic blood pressure > 110 mm Hg).
- •5) Symptomatic postural hypotension within 6 months of Visit 1.
- •6) History of congenital QT prolongation.
- •7) Bleeding disorder.
- •8) History of prostatectomy because of prostate cancer, including nerve-sparing techniques.
- •Clarification: Any surgical procedures for the treatment of Benign Prostate Hypertrophy (BPH) are permitted, with the exception of cryosurgery, cryotherapy or cryo-ablation.
- •9) Hereditary degenerative retinal disorders such as retinitis pigmentosa.
- •10) History of loss of vision because of NAION, temporary or permanent loss of vision, including unilateral loss of vision.
- •11) Presence of penile anatomical abnormalities/deviations, e.g. due to Peyronie’s disease which, in the investigator’s opinion would significantly impair sexual performance.
- •12) Clinically significant chronic hematological disease which may lead to priapism, such as sickle cell anaemia, multiple myeloma, and leukaemia.
- •13) Primary hypoactive sexual desire.
- •14) Spinal cord injury.
- •15) Active peptic ulceration.
- •16) History of malignancy within the past 5 years (other than squamous or basal cell skin cancer).
- •17) Severe chronic or acute liver disease, history of moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment.
- •18) History of positive test for Hepatitis B surface antigen (HbsAg) or Hepatitis C.
- •19) History of documented elevation of AST and/or ALT > 3 times the upper limit of the normal range (laboratory-specific).
- •20) Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject’s participation in the study.
- •21) Patients with evident clinical signs of hypogonadism and/or documented total plasma testosterone < 12 nmol/L.
- •22) Subjects with known renal insufficiency defined according to the following thresholds of documented laboratory data: Serum creatinine > 3.0 mg/dL and/or creatinine clearance (calculated) < 30.0 ml/min.
- •B) Concomitant medications
- •1) Subjects who are taking nitrates or nitric oxide donors.
- •2) Subjects who are exposed to androgens irrespective of their mode of administration.
- •3) Subjects who are taking anti-androgens.
- •4) Subjects who are taking alpha-blockers.
- •5) Subjects who are taking one or more of the following potent inhibitors of cytochrome P450 3A4: HIV protease inhibitors such as ritonavir or indinavir, the anti-mycotic agents itraconazole or ketoconazole (topical forms are allowed), and the macrolide antibiotics clarithromycin and erythromycin.
- •6) Subjects who are taking medications known to prolong the QT interval, such as Type Ia and Type 3 anti-arrhythmic drugs.
- •7) Subjects who have received any investigational drug (including placebo) within 30 days of Visit 1.
- •8) Use of any treatment for ED during the entire study (i.e. subsequent to Visit 1
研究者
相似试验
已完成
不适用
Double-blind, placebo-controlled, randomized study to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of ACT-541468: Part A: Multiple-ascending doses in healthy young adults after morning administration. Part B: Single-ascending doses in healthy elderly subjects after morning administration. Part C: Repeated doses in both healthy young adults and elderly subjects after evening administration.insomniaSleeping disorderssleeping disorderNL-OMON42430Actelion Pharmaceuticals84
招募中
不适用
Double-blind, randomized, placebo controlled study to REduce STEroids in Relapsing Nephrotic syndromeNL-OMON47536Radboud Universitair Medisch Centrum80
进行中（未招募）
1 期
Efficacy, safety, and tolerability of Ancrod in patients with sudden hearing losssudden sensorineural hearing loss (SSHL)MedDRA version: 20.0Level: LLTClassification code 10040016Term: Sensorineural hearing lossSystem Organ Class: 100000013775EUCTR2012-000066-37-CZordmark Arzneimittel GmbH & Co. KG115
进行中（未招募）
1 期
Efficacy, safety, and tolerability of Ancrod in patients with sudden hearing losssudden sensorineural hearing loss (SSHL)MedDRA version: 20.0Level: LLTClassification code 10040016Term: Sensorineural hearing lossSystem Organ Class: 100000004854EUCTR2012-000066-37-DEordmark Arzneimittel GmbH & Co. KG115
招募中
3 期
Activity of Curcumin derivative on Joint Inflammation (knees) of the patients.CTRI/2023/09/058104Sam Sabinsa Group Limited